Active, not recruitingPhase 2NCT07544537

A Prospective Comparative Study of Autologous Bone Marrow-Derived and Adipose Tissue-Derived Mesenchymal Stem Cells Versus Platelet-Rich Plasma and Standard Therapy in Patients With Organic Erectile Dysfunction

Studying Rapidly involuting congenital hemangioma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Scientific Medical Center, Kazakhstan
Principal Investigator
Manarbek Askarov, PhD
National Scientific Medical Center
Intervention
Autologous Bone marrow-derived Mesenchymal Stem Cells (BMSC)(biological)
Enrollment
100 target
Eligibility
18-70 years · MALE
Timeline
20242026

Study locations (1)

Collaborators

Medical Center Medi-Art

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07544537 on ClinicalTrials.gov

Other trials for Rapidly involuting congenital hemangioma

Additional recruiting or active studies for the same condition.

See all trials for Rapidly involuting congenital hemangioma

← Back to all trials